Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.63 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.63 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.56 |
| ▸ | FDPS | P14324 | 10/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258070 | 0.84 | SMPD1 (0.46) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| SCHEMBL8976975 | 0.82 | LPAR3 (0.75) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| SCHEMBL28687765 | 0.81 | LPAR3 (0.62) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| SCHEMBL28379716 | 0.81 | LPAR3 (0.61) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| SCHEMBL17887206 | 0.81 | LPAR3 (0.56) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL27692367 | 0.81 | LPAR3 (0.95) | LPAR3LPAR1LPAR2SMPD1 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL28883739 | 0.81 | LPAR3 (0.95) | LPAR3LPAR1LPAR2SMPD1 | |
| Phosphoric Acid Monotetradecyl Ester SCHEMBL28415986 | 0.79 | LPAR3 (0.84) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| SCHEMBL28690764 | 0.79 | LPAR3 (0.84) | LPAR3LPAR1LPAR2SMPD1FDPS | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL28681645 | 0.79 | LPAR3 (0.84) | LPAR3LPAR1LPAR2SMPD1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | LPAR3 77/4885LPAR1 26/4885LPAR2 79/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | LPAR3 54/4885LPAR1 43/4885LPAR2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.